Tax Reform in This Election Year: It's Not Likely
Which Credit Card Rewards Does the IRS Care About?
Dendreon (NASDAQ: DNDN) expects the Independent Data Monitoring Committee (IDMC) to review in October 2008 the interim analysis of overall survival relating to the Company's Phase 3 IMPACT (Immunotherapy for Prostate AdenoCarcinoma Treatment). DNDN November call option implied volatility is at 164, puts are at 195; above its 26-week average of 129 according to Track Data, suggesting larger price fluctuations.
Savient Pharma (NASDAQ: SVNT) closed at $21.95 Thursday. SVNT's Puricase (treatment for refractory gout) BLA (biologics license application) filing is expected this autumn. SVNT September and October option implied volatility is at 86, December is at 82. SVNT average option implied volatility over the last 26-weeks is 79 according to Track Data, suggesting larger price movement.
Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
